AIDS

Home Current Issue Previous Issues Published Ahead-of-Print Collections For Authors Journal Info
Skip Navigation LinksHome > May 31, 2008 - Volume 22 - Issue 9 > Potential role of CD8+CD28- T lymphocytes in immune activati...
AIDS:
31 May 2008 - Volume 22 - Issue 9 - p 1083-1086
doi: 10.1097/QAD.0b013e3282fce613
Research Letters

Potential role of CD8+CD28- T lymphocytes in immune activation during HIV-1 infection

Vivar, Nancy; Thang, Pham Hong; Atlas, Ann; Chiodi, Francesca; Rethi, Bence

Free Access
Article Outline
Collapse Box

Author Information

aDepartment of Microbiology, Cell and Tumor Biology, Karolinska Institute, Stockholm, Sweden

bNational Institute of Hygiene and Epidemiology, Hanoi, Vietnam

cDepartment of Medicine, Infectious Diseases Unit, Karolinska University Hospital, Solna, Sweden

dInstitute of Immunology, University of Debrecen, Debrecen, Hungary.

Correspondence to Bence Rethi, PhD, Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Nobels väg 16, Stockholm S-17177, Sweden. Tel: +46 8 52486775; fax: +46 8304276; e-mail: Bence.Rethi@ki.se

Collapse Box

Abstract

As CD8+CD28- T cells have been associated with dendritic and T cell suppression, we analyzed whether an increase in CD8+CD28- T cell numbers during HIV-1 infection could lead to impaired T cell responses. In contrast to the in-vitro generated CD8+CD28- suppressors, peripheral blood CD8+CD28- T cells of both HIV-infected and noninfected individuals promoted dendritic cell activation. The CD8+CD28- T cell accumulation during HIV-1 infection may thus contribute to accelerated inflammatory reactions and immune activation.

The CD28- T cell pool is expanded in the peripheral blood of HIV-1 infected or aged individuals reaching up to 80% among CD8+ T cells [1-4]. CD28- T cells, as indicated by several studies [1,4-8], represent chronically expanded clones specific for a limited set of antigens and characterized by impaired proliferative ability.

Interestingly, CD8+ T cell subsets characterized by immunosuppressive functions were also associated with the lack of CD28 expression [9]. These cells were generated through repeated in-vitro allogenic stimulations (type 1 suppressor T cells) or in cultures with autologous monocytes, granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin (IL)-2 (type 2 suppressor T cells). The suppressor T cells exert their immunosuppressive effects on T cell activation by modulating the T cell activatory potential of dendritic cells or by directly affecting activated T cells through soluble mediators (type I and type II suppressor T cells, respectively) [9,10]. Decreased activity of CD8+CD28- suppressor T cells has been associated with the increased risk of transplant rejections, with the active phase of systemic lupus erythematosus, and with HIV-1 infection providing a potential link between suppressor T cell activity and tolerance regulation in vivo [9,11,12]. In these studies, however, the detection of any CD8+CD28- suppressor activity required extensive in-vitro induction procedures, including either sequential antigenic stimulation or treatments with GM-CSF, IL-2 and monocytes [9,11-14]. Whether CD8+CD28- T cells occurring in vivo are able to elicit suppressor activity per se and under what circumstances the CD28- suppressor T cells develop from their precursors are questions yet to be clarified.

It is intriguing to speculate that the high number of CD28- T cells existing in HIV-1 infected individuals may result in the altered frequency of potential suppressor T cell types and thus may contribute to immune insufficiencies leading to inappropriate T cell responses against HIV, opportunistic infections and malignant cells. FoxP3 expression, detected in the in-vitro generated CD28- T suppressor cells and the decreased IL-7Rα expression on peripheral blood CD28- T cells indicate similarities between CD8+CD28- T cells and CD4+ regulatory T cells [15-17]. In the present study, we analyzed whether the CD28- T cells isolated from peripheral blood of HIV-1 infected or noninfected individuals contain FoxP3+ cells that are able to elicit suppressor activity on dendritic cell functions or T cell activation. Blood samples were obtained from 12 HIV-1 infected patients (nine on combination therapy, three treatment naïve, viral load ranged between <50 and 139 000 copies/ml, mean CD4+ T cell count was 474 cells/μl) and from eight noninfected donors.

Our results showed that the CD8+CD28- T cells were FoxP3-negative in all HIV-1 infected (n = 5) and noninfected individuals (n = 5) tested whereas the expression of FoxP3 was exclusively associated with the CD28+ CD4+ IL-7Rα low T cells in the peripheral blood (Fig. 1a,b). We sought to analyze systematically how CD28- T cells isolated from HIV-1 infected or noninfected individuals may influence dendritic cell and T cell activation. CD28+ and CD28- T cell subsets were purified from the peripheral blood of HIV-1 infected (n = 3) and noninfected (n = 3) individuals and then cultured with monocyte-derived dendritic cells for 24 h. The dendritic cells were then activated with lipopolysaccharide (LPS) or left without further treatment for 24 h and thereafter the expression of HLA-DQ, CD83 and CD86, three markers of dendritic cell activation, was analyzed. Interestingly, the presence of both CD28+ and CD28- T cell subsets induced the upregulation of these molecules (Fig. 1c) and none of the T cell populations interfered with LPS-induced maturation (data not shown). The lack of dendritic cell suppression by CD28- T cells is in striking contrast to the effect of the in-vitro generated CD28- T suppressor cells characterized by an inhibitory potential for phenotypic dendritic cell maturation [9]. The effect of purified CD28+ and CD28- T cells was also tested on cytokine production by dendritic cells. Instead of any inhibitory effect of CD28- T cells, this population strongly augmented LPS-induced IL-12 and tumor necrosis factor (TNF) production of dendritic cells, whereas IL-10 secretion was not influenced by the presence of any T cell subsets (Fig. 1d).

Fig. 1
Fig. 1
Image Tools

The most characteristic function associated with CD28- suppressor T cells generated in vitro is their profound ability to inhibit proliferation of other T cells either by dendritic cell modulation or through directly interfering with T cell activation [9,10]. We analyzed whether CD28- T cells isolated from HIV-1 infected (n = 3) or noninfected (n = 3) individuals were able to influence the proliferation of naïve T cells triggered by dendritic cells and anti-CD3. The CD28-, CD28+ and CD28+CCR7- peripheral blood T cells were cultured with dendritic cells for 24 h and, thereafter, purified naïve T cells were added to the cultures and triggered by 2 μg/ml of anti-CD3 mAbs. CD28+ or CD28- T cells preincubated with dendritic cells minimally influenced the proliferation of third party T cells. The ratio of T cells undergoing cell divisions changed 0.9 ± 0.1-fold and 1.0 ± 0.1-fold (in the presence of CD28+ and CD28- T cells, respectively, for HIV-infected donors) or alternatively, 1.1 ± 0.2-fold and 0.8 ± 0.1-fold (in the presence of CD28+ and CD28- T cells, respectively, for noninfected donors) as compared with untreated dendritic cells. The slight reduction in the number of proliferating cells detected in the presence of CD28- T cells of noninfected individuals was similarly observed when the CD28+CCR7- memory subset was added to the dendritic cell cultures (Fig. 1e), possibly indicating negative feedback mechanisms delivered by previously antigen-encountered T lymphocytes, which might compromise any further T cell activation. This inhibitory effect was, however, not CD28- T cell-specific.

Importantly, CD28- T cell mediated dendritic cell activation and the lack of any CD28- T cell specific suppression of T cell proliferation were equally observed in the case of both HIV-1 infected and noninfected donors. These results suggest that the accumulation of CD28- peripheral T cells during HIV-1 infection may not lead to increased frequency of T suppressor cells or precursors prone to readily differentiate into T suppressor cells in the presence of dendritic cells and activated T cells. We observed that the CD28- T cells elicited dendritic cell stimulatory effects, suggesting that the accumulation of CD28- T cells in HIV-1 infected individuals, instead of leading to dendritic cells or T cell suppression, may contribute to accelerated inflammatory reactions and immune activation.

Back to Top | Article Outline

Acknowledgements

The study was supported by grants received from the Swedish MRC, the Swedish International Development Agency (SIDA-SAREC). Bence Rethi was supported by the Hungarian State Eötvös Fellowship.

Back to Top | Article Outline

References

1. Effros RB. Impact of the Hayflick Limit on T cell responses to infection: lessons from aging and HIV disease. Mech Ageing Dev 2004; 125:103-106.

2. Kammerer R, Iten A, Frei PC, Burgisser P. Expansion of T cells negative for CD28 expression in HIV infection. Relation to activation markers and cell adhesion molecules, and correlation with prognostic markers. Med Microbiol Immunol 1996; 185:19-25.

3. Trimble LA, Shankar P, Patterson M, Daily JP, Lieberman J. Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3zeta and CD28, key signaling molecules for T-cell activation. J Virol 2000; 74:7320-7330.

4. Appay V, Rowland-Jones SL. Premature ageing of the immune system: the cause of AIDS? Trends Immunol 2002; 23:580-585.

5. Clambey ET, van Dyk LF, Kappler JW, Marrack P. Nonmalignant clonal expansions of CD8+ memory T cells in aged individuals. Immunol Rev 2005; 205:170-189.

6. Ouyang Q, Wagner WM, Wikby A, Walter S, Aubert G, Dodi AI, et al. Large numbers of dysfunctional CD8+ T lymphocytes bearing receptors for a single dominant CMV epitope in the very old. J Clin Immunol 2003; 23:247-257.

7. Pawelec G, Akbar A, Caruso C, Solana R, Grubeck-Loebenstein B, Wikby A. Human immunosenescence: is it infectious? Immunol Rev 2005; 205:257-268.

8. Weekes MP, Carmichael AJ, Wills MR, Mynard K, Sissons JG. Human CD28-CD8+ T cells contain greatly expanded functional virus-specific memory CTL clones. J Immunol 1999; 162:7569-7577.

9. Chang CC, Ciubotariu R, Manavalan JS, Yuan J, Colovai AI, Piazza F, et al. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 2002; 3:237-243.

10. Filaci G, Suciu-Foca N. CD8+ T suppressor cells are back to the game: are they players in autoimmunity? Autoimmun Rev 2002; 1:279-283.

11. Filaci G, Rizzi M, Setti M, Fenoglio D, Fravega M, Basso M, et al. Nonantigen-specific CD8(+) T suppressor lymphocytes in diseases characterized by chronic immune responses and inflammation. Ann N Y Acad Sci 2005; 1050:115-123.

12. Filaci G, Bacilieri S, Fravega M, Monetti M, Contini P, Ghio M, et al. Impairment of CD8+ T suppressor cell function in patients with active systemic lupus erythematosus. J Immunol 2001; 166:6452-6457.

13. Filaci G, Fenoglio D, Fravega M, Ansaldo G, Borgonovo G, Traverso P, et al. CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol 2007; 179:4323-4334.

14. Suciu-Foca N, Manavalan JS, Cortesini R. Generation and function of antigen-specific suppressor and regulatory T cells. Transpl Immunol 2003; 11:235-244.

15. Rethi B, Fluur C, Atlas A, Krzyzowska M, Mowafi F, Grutzmeier S, et al. Loss of IL-7Ralpha is associated with CD4 T-cell depletion, high interleukin-7 levels and CD28 down-regulation in HIV infected patients. AIDS 2005; 19:2077-2086.

16. Scotto L, Naiyer AJ, Galluzzo S, Rossi P, Manavalan JS, Kim-Schulze S, et al. Overlap between molecular markers expressed by naturally occurring CD4+CD25+ regulatory T cells and antigen specific CD4+CD25+ and CD8+CD28- T suppressor cells. Hum Immunol 2004; 65:1297-1306.

17. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203:1693-1700.

© 2008 Lippincott Williams & Wilkins, Inc.